Factors Influencing Blood Concentration of Voriconazole and Therapeutic Drug Monitoring in Patients with Child–Pugh Class C Cirrhosis
Table 1
Demographic and clinical characteristics of 66 patients with Child–Pugh class C cirrhosis and indications for voriconazole therapy.
Characteristics
No. of patients (n = 66)
Demographics
Sex (male/female) (n)
52/14
Age (years) (mean ± SD)
53.2 ± 13.4
Nationality (Han/Korean)
65/1
BMI (kg/m2) (mean ± SD)
23.1 ± 4.0
NMs : IMs : PMs (n)
28 : 25 : 13
Cause of liver disease (n (%))
Viral hepatitis
31 (47.0)
Hepatitis B
26 (39.4)
Hepatitis C
5 (7.6)
Alcoholic liver disease
14 (21.2)
Liver transplantation
2 (3.0)
Cryptogenic cirrhosis
4 (6.1)
Other cause liver cirrhosis
15 (22.7)
Drug-induced liver injury
6 (9.1)
Autoimmune liver disease
5 (7.6)
Malignant tumor of liver
2 (3.0)
Hepatolenticular degeneration
2 (3.0)
Site of IFIs (n (%))
Pulmonary
62 (94.0)
Abdominal cavity
1 (1.5)
Urinary system
2 (3.0)
Biliary tract
1 (1.5)
Fungal organisms (n (%))
Proven IFIs
1 (1.5)
Probable IFIs
30 (45.5)
Possible IFIs
35 (53.0)
IFIs, invasive fungal infections; IMs, intermediate metabolizers of the CYP2C19 phenotype; NMs, normal metabolizers of the CYP2C19 phenotype; PMs, poor metabolizers of the CYP2C19 phenotype.
